SVB Leerink Analysts Lower Earnings Estimates for Repligen C

Repligen Co. (NASDAQ:RGEN – Get Rating) – Equities research analysts at SVB Leerink dropped their Q1 2023 earnings per share estimates for Repligen in a research report issued on Wednesday, October 19th. SVB Leerink analyst P. Souda now anticipates that the biotechnology company will post earnings of $0.81 per share for the quarter, down from […]

Related Keywords

United States , America , Anthony Hunt , Asia Pacific , Jon Snodgres , Pendal Group Ltd , Securities Exchange Commission , Repligen Corporation , Repligen Co , Nasdaq , Artisan Partners Limited Partnership , Keycorp , Pricet Rowe Associates Inc , William Blair Investment Management , Repligen Company Profile , Get Rating , Exchange Commission , Partners Limited Partnership , Blair Investment Management , Group Ltd , North America , Repligen Daily , Repligen , Nasdaq Rgen , Rgen , Medical , 75991610 , Earnings Estimates , Svb Leerink Llc ,